|
June. 29, 2021 |
|
|
Nov. 15, 2024 |
|
|
jRCT2031210172 |
ONO-7913-03:An open-label, uncontrolled study of ONO-7913 and ONO-4538 in combination with modified FOLFIRINOX as first-line treatment in patients with metastatic pancreatic cancer |
|
ONO-7913-03: ONO-7913 Phase 1 Study |
Hirashima Yoshinori |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120626190 |
||
clinical_trial@ono-pharma.com |
||
Center Information Medical |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120626190 |
||
clinical_trial@ono-pharma.com |
Not Recruiting |
July. 01, 2021 |
||
| July. 30, 2021 | ||
| 30 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
1. Untreated metastatic pancreatic cancer |
||
1. Patients with severe complication |
||
| 20age old over | ||
| No limit | ||
Both |
||
Untreated metastatic pancreatic cancer |
||
Administration of ONO-7913 and ONO-4538 in combination with mFFX therapy |
||
Tolerability, safety |
||
| Ono Pharmaceutical Co.,LTD |
| Kanagawa Cancer Center Research Ethics Review Board | |
| 2-3-2, Nakao, Asahi,Yokohama, Kanagawa | |
+81-45-520-2222 |
|
| Approval | |
July. 12, 2021 |
No |
| NCT06532344 |
none |